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B I O C H E M I S T R Y
Multiple modes of PRC2 inhibition elicit global 
chromatin alterations in H3K27M pediatric glioma
James M. Stafford1,2*, Chul-Hwan Lee1,2*, Philipp Voigt1†, Nicolas Descostes1,2,  
Ricardo Saldaña-Meyer1,2, Jia-Ray Yu1,2, Gary Leroy1,2, Ozgur Oksuz1,2, Jessica R. Chapman3‡, 
Fernando Suarez4,5, Aram S. Modrek4,6, N. Sumru Bayin4,6, Dimitris G. Placantonakis4,6,7,8, 
Matthias A. Karajannis4,5§, Matija Snuderl4,9, Beatrix Ueberheide1,3, Danny Reinberg1,2‖
A methionine substitution at lysine-27 on histone H3 variants (H3K27M) characterizes ~80% of diffuse intrinsic 
pontine gliomas (DIPG) and inhibits polycomb repressive complex 2 (PRC2) in a dominant-negative fashion. Yet, 
the mechanisms for this inhibition and abnormal epigenomic landscape have not been resolved. Using quantita-
tive proteomics, we discovered that robust PRC2 inhibition requires levels of H3K27M greatly exceeding those of 
PRC2, seen in DIPG. While PRC2 inhibition requires interaction with H3K27M, we found that this interaction on chro-
matin is transient, with PRC2 largely being released from H3K27M. Unexpectedly, inhibition persisted even after 
PRC2 dissociated from H3K27M-containing chromatin, suggesting a lasting impact on PRC2. Furthermore, allosteri-
cally activated PRC2 is particularly sensitive to H3K27M, leading to the failure to spread H3K27me from PRC2 
recruitment sites and consequently abrogating PRC2’s ability to establish H3K27me2-3 repressive chromatin 
domains. In turn, levels of polycomb antagonists such as H3K36me2 are elevated, suggesting a more global, 
downstream effect on the epigenome. Together, these findings reveal the conditions required for H3K27M- 
mediated PRC2 inhibition and reconcile seemingly paradoxical effects of H3K27M on PRC2 recruitment and activity.
INTRODUCTION
Histones form the core DNA packaging material in the nucleus. Even 
slight alterations in their amino acid composition can have dramatic 
consequences on chromatin structure, affecting gene expression and 
genome integrity (1). One of the most marked examples is the lysine- 
to-methionine (K-to-M) substitution at residue 27 on canonical 
histone H3.1 or its variant H3.3 (H3K27M). These mutations were 
found in ~80% of diffuse intrinsic pontine gliomas (DIPG), one of the 
most deadly and difficult-to-treat pediatric cancers (2). Despite affecting 
only 1 of 15 copies of the H3 genes, the presence of H3K27M sig-
nificantly impairs the activity of polycomb repressive complex 2 
(PRC2), leading to a drastic reduction and redistribution of di- and 
trimethylation of H3K27 (H3K27me2 and H3K27me3, respectively) 
(3–6) in the affected cells. These effects of H3K27M on PRC2, 
as well as those on the chromatin landscape, have been linked to 
oncogenic transcriptional programs that give rise to the cancer stem 
cell–like and proliferative properties of DIPG (4, 7, 8). Therefore, un-
derstanding the underlying mechanisms of how H3K27M affects 
PRC2 and the global epigenetic landscape is imperative for under-
standing DIPG, and ultimately, devising strategic ways to overcome 
the oncogenic potential of H3K27M.
Following the discovery of H3K27M, a hypothesis suggesting 
that H3K27M traps and sequesters PRC2, thereby diminishing its 
activity, emerged (3). Supporting evidence came from the observation 
that PRC2 has a higher affinity for H3K27M relative to WT H3K27 
(H3K27WT) peptides and nucleosomes (4, 9). Moreover, structural 
studies revealed that H3K27M occupies the catalytic su(var)3-9, 
enhancer-of-zeste and trithorax (SET) domain of enhancer-of-zeste 
homolog 2 (EZH2), preventing the hydrolysis of the methyl donor 
S-adenosylmethionine (SAM) and the release of EZH2 (3, 4, 9). 
However, in vivo studies indicate that the genomic localization of 
H3K27M is often inversely correlated with PRC2 occupancy, challeng-
ing the idea that H3K27M sequesters PRC2 on chromatin (6, 10, 11). 
Notably, despite a drastic loss in H3K27me3 in affected cells, some 
loci retained PRC2 and H3K27me3 at abnormally high levels in 
H3K27M-expressing cells (4, 5, 12). Additional layers of com plexity 
came from studies showing that H3K27M does not have consistent 
effects in all cell types (7, 8) nor is it able to strongly interact with 
PRC2 in all chromatin contexts (6, 13). Therefore, a model whereby 
H3K27M stably sequesters PRC2 on chromatin cannot explain all 
observations, indicating that further study is required to resolve these 
disparate observations and to uncover the mechanism(s) by which 
H3K27M affects PRC2 and the chromatin landscape in DIPG. This 
study aims to reconcile these findings by combining isogenic and 
patient-derived model systems to better understand the dynamic and 
nuanced impact of H3K27M on PRC2 while placing those effects in the 
molecular and broader chromatin context.
RESULTS
H3K27M-to-PRC2 ratio dictates the degree of PRC2 inhibition
Perhaps the most studied hypothesis for dominant-negative inhibi-
tion of PRC2 by H3K27M is that H3K27M sequesters PRC2, prevent-
ing it from methylating most of H3K27WT nucleosomes (3, 4, 9, 14). 
This hypothesis relies on two assumptions, namely, that H3K27M is 
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more abundant than PRC2 and that PRC2 has a higher affinity for 
H3K27M- than H3K27WT-containing nucleosomes. Therefore, 
precise quantification of PRC2 relative to H3K27 methylation 
(H3K27me) and H3K27M levels in DIPGs and comparable cell 
types is essential for understanding how the cellular stoichiometry 
of these factors contributes to cellular sensitivity to H3K27M. We hy-
pothesized that the levels of PRC2 might render DIPG particularly 
sensitive to H3K27M, given their profound loss in H3K27me2-3 rel-
ative to other brain tumors and cell types in the neural lineage (Fig. 1A).
Testing this hypothesis required a quantitative measure of PRC2 
molecules per cell, leading us to develop an MS parallel reaction 
monitoring assay (15). Briefly, PRC2 core proteins [EZH2, embryonic 
ectoderm development (EED), and suppressor of zeste homolog 12 
(SUZ12)] were quantified with a targeted method using heavy isotope- 
labeled synthetic peptides as internal standards (fig. S1, A to C, and 
data file S1). Our approach revealed a wide range of PRC2 levels across 
different cell types, with CRISPR- generated H3K27M (on H3F3A) 
E14 mESCs containing relatively high PRC2 levels (~150,000 PRC2 
molecules per cell; Fig. 1B and fig. S1D). In our isogenic mESC and 
293 T-REx system below, we chose H3.3K27M, as it is the most fre-
quently occurring H3K27M mutation (2). H3K27M DIPGs (both 
H3.1K27M and H3.3K27M DIPGs) were at the lower end of the 
spectrum (~5 to 10,000 PRC2 molecules per cell; fig. S1D). By com-
paring the levels of PRC2 with those of H3K27M, as determined by 
relative quantitative histone MS, we observed that H3K27M- bearing 
DIPG exhibited ~100-fold excess of H3K27M over PRC2 (Fig. 1B and 
see table S1 for details on cell lines). In accordance, H3K27M-bearing 
DIPGs showed a robust loss in H3K27me2-3 deposition relative to 
WT DIPG (Fig. 1B). Similarly, 293 T-REx cells with inducible expres-
sion of H3K27M (H3.3K27M) also showed a large excess of H3K27M 
relative to PRC2 (more than 200-fold) and a substantial deficit in 
H3K27me2-3. However, mESC harboring H3.3K27M showed only 
a modest loss in H3K27me2-3, relative to WT mESC. Given that 
H3K27M was only in ~10-fold excess of PRC2 in mESC, the results 
suggested that H3K27M must be largely in excess of PRC2 to achieve 
the robust decrease in H3K27me2-3 seen in DIPG and other cell 
types. These results are consistent with previous speculation that 
high amounts of a K-to-M mutation are needed to inhibit various 
HMTs (3, 16).
To test whether shifting the relative abundance of H3K27M and 
PRC2 during lineage commitment could alter sensitivity to H3K27M 
inhibition, we differentiated H3.3K27M mESC as described above 
into cervical mNEURON precursors (Fig. 1C) (17). Our quantitative 
MS revealed that PRC2 decreased as cells proceeded down the 
mNEURON lineage to levels consistent with those seen in DIPG 
(5 to 10,000 molecules per cell; fig S1). We observed that K27M 
produced a greater loss of H3K27me2-3 in mNEURON than was 
seen in undifferentiated mESC (Fig. 1D). Although we cannot rule 
out the contribution of an unknown factor(s) during the differenti-
ation process, these results, together with those analyzing the quan-
titative H3K27M-to-PRC2 ratio in different cells, demonstrate that 
the critical force for the H3K27me3 reduction is due to the large 
excess of K27M over PRC2. These observations are consistent with 
K27me2-3 loss when the H3K27M-to-PRC2 ratio is high, which 
we tested directly using an HMT assay in a fully biochemically re-
constituted system (Fig. 1E). The addition of increasing amounts 
of recombinant oligonucleosomes comprising H3K27M gave rise to 
heightened sensitivity of PRC2 to inhibition, while the control using 
oligonucleosomes where lysine-27 was mutated to alanine (H3K27A) 
was ineffectual (Fig.  1E). Together, the quantitative approach 
measuring H3K27M-to-PRC2 ratio in different cell lines including 
patient-derived DIPG model systems, as well as the in vitro dif-
ferentiation studies together with the biochemical approach, revealed 
that cells containing low amounts of PRC2, relative to H3K27M such 
as DIPG, mNEURONs, and 293 T-REx, are sensitive to H3K27M- 
mediated inhibition of PRC2 activity.
PRC2 is transiently recruited to H3K27M-containing chromatin
Given the high excess of H3K27M to PRC2 in DIPG (Fig. 1B) and 
the higher affinity of PRC2 for H3K27M in vitro, H3K27M would 
be expected to sequester all PRC2 in a DIPG cell (3, 9, 16). However, 
the following observations argue against this assumption: (i) PRC2 
and H3K27M often do not colocalize on chromatin under some con-
ditions of steady-state H3K27M expression, as measured by chro-
matin immunoprecipitation (ChIP) (6, 10, 18); and (ii) H3K27me3 
can be retained at specific loci and redistributed in H3K27M cells 
(4–6, 10, 12). Reasoning that the steady-state dynamics between 
H3K27M and PRC2 reflect only the outcome of this dysregulated pro-
cess, we sought a means to detect changes in the interaction between 
H3K27me3 and PRC2 and subsequent effects on PRC2 as a function 
of the rate of H3K27M deposition. To this end, we used an inducible 
expression system in 293 T-REx cells to monitor the early and later 
events following H3K27M expression (Fig. 2A). This inducible system 
recapitulated the global loss of H3K27me2-3 seen in H3K27M-bearing 
DIPG (Figs. 2B and 1A). Spike-in normalized ChIP sequencing (ChIP-seq) 
experiments across this time course revealed that PRC2 primarily co-
localized with H3K27M at early time points, namely, after 6 and 12 hours 
of expression, but was largely excluded from H3K27M sites at the late, 
24-hour time point (Fig. 2C, left). Genome- wide analysis indicated that 
there are nearly 1500 PRC2-occupied domains unique to the 6- and 
12-hour time points that are not present at 24 hours (Fig. 2C, right). Those 
early PRC2 loci are only seen in H3K27M-, but not in H3K27WT- 
expressing, cells and colocalized with H3K27M (Fig. 2C). Combined 
with the higher affinity of PRC2 for H3K27M nucleosomes [(4) and 
see below] and peptides (9), our results demonstrate that H3K27M- 
containing nucleosomes transiently recruit PRC2 to loci not typically 
occupied by PRC2 in a WT setting, leading to the aberrant deposition 
of PRC2 early after H3K27M expression (Fig. 2).
Given the transient nature of PRC2 recruitment to H3K27M, 
numerous factors might contribute to its eviction, including the 
known PRC2 antagonist, H3K36me2, especially when it occurs 
directly adjacent to H3K27M (i.e., in cis). Western blot analysis of 
extracts derived from the inducible 293 T-REx system revealed en-
richment of H3K36me2 on H3.3K27M histones, supporting their 
co-occurrence in cis, which coincided with a loss of H3K27me2-3 
(Fig. 2B). This was particularly evident in H3K27M-bearing DIPG, 
where MS revealed that H3K36me2 was overwhelmingly the pre-
dominant modification adjacent to H3K27M, regardless of whether 
it was H3.1K27M or H3.3K27M (fig. S2A). In our time course studies, 
a strong co-occurrence in cis of H3K36me2 and H3K27M emerged 
at 24 hours, at which time EZH2 occupancy at H3K27M-containing 
loci is lost, relative to earlier time points (Fig. 2B). Therefore, even-
tual PRC2 eviction and stable exclusion from K27M loci might be 
related to H3K36me2 deposition, presumably by preventing PRC2 
interaction with the H3 N-terminal tail (19–22). Other antagonistic 
modifications such as histone acetylation might also contribute, as 
has been suggested by others [(6, 13) and see our data below]. In a 
broad sense, the deposition of H3K27M largely into transcriptionally 
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active regions in both the isogenic K27M 293 T-REx and K27M 
DIPG cells themselves (fig. S2B) suggests a dynamic environment 
wherein histone modifications associated with transcription activity 
[this study and (6, 13)], histone turnover (23), and even nascent 
mRNA might lead to the failure of K27M to stably recruit PRC2 
[i.e., the eviction of PRC2 (11, 24)]. While we cannot exclude the 
possibility that the release of PRC2 from H3K27M arises from a 
more direct effect on PRC2 itself (see Discussion), we expect that 
future studies will find that the interaction and release of PRC2 
from H3K27M are determined by the interplay between the local 
chromatin environment and structural changes to PRC2 itself.
Persistent inhibition of PRC2 after its dissociation  
from H3K27M
We next sought to better understand the impact of H3K27M on 
PRC2 activity at more typical PRC2 target sites. First, we identified 
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by H3K27M protein expression. (D) Left: Western blot validating the cell lines and increased K27M expression with significantly reduced levels of PRC2 core components 
in mNEURON. Islet1/2 served as an mNEURON marker. Right graph: Differentiation to mNEURON led to decreased K27me2-3 in K27M cells, relative to their mESC precursors, 
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616 broad PRC2 (EZH2) domains present in both H3K27M and 
H3K27WT cells across all time points and found that, despite the 
retention of EZH2 at a subset of genes at 24 hours in H3K27M cells, a 
global loss of H3K27me3 was evident (Fig. 3A and fig. S3 for visual-
ization of the broad domains). As the cells progressed, attaining steady- 
state levels of H3K27M, the loss in H3K27me3 was even greater 
in magnitude, despite the retention of EZH2 and the lack of H3K27M 
enrichment at those same sites after 72 hours of H3K27M expression 
(Fig. 3B). Together, these results are consistent with recent work show-
ing that loci depleted of H3K27me3 in H3K27M cells have equal 
PRC2 occupancy and with emerging evidence that PRC2 recruitment 
can be uncoupled from its enzymatic activity [(5, 25) and see below].
We next investigated whether the interaction of PRC2 with 
H3K27M-containing nucleosomes might have a lasting impact on 
its function. This was motivated by our observations (i) that newly 
expressed K27M deposits at sites that are not usually regulated by 
PRC2 and PRC2 are transiently recruited at these new sites and (ii) 
that some PRC2-regulated genes maintain PRC2, but its activity is 
reduced in H3K27M cells (Figs. 2 and 3). To study this, we 
expressed tagged PRC2 in H3K27M- and H3K27WT-expressing 293 
T-REx cells (fig. S4, A and B). PRC2 was then purified using a com-
bination of conventional and tandem affinity chromatography, 
yielding PRC2 in correct stoichiometry between samples (Fig. 4A). 
H3K27M was not detected by Western blotting and MS analysis in 
the purified PRC2 fractions (Fig. 4A and fig. S4C). We found that 
the catalytic activity of PRC2 purified from H3K27M-expressing 
cells was markedly decreased relative to PRC2 purified from 
H3K27WT cells and that this inhibition was SAM dependent (Fig. 4B), 
which is consistent with the previous observation demonstrating that 
SAM is necessary for inhibition of the methyltransferase by K-to-M 
mutation on histone H3 (26). This lasting H3K27M inhibitory ef-
fect on PRC2 was also observed using a system reconstituted with 
all recombinant components, including PRC2 comprising only its 
four core subunits (EZH2, EED, SUZ12, and RBAP48; Fig. 4C) and 
oligonucleosomes formed with bacterially expressed histones (Fig. 4D). 
After release from H3K27M-containing oligonucleosomes, the 
resultant PRC2 was generally less active (Fig. 4E), in line with a widespread 
attenuation of H3K27me2-3 in K27M DIPG. Given that lasting PRC2 
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inhibition is seen in vivo and within a fully recombinant system, we 
speculate that H3K27M-containing chromatin alters the core PRC2 
complex through a stable conformational change (see Discussion).
Inhibition of allosteric activation of PRC2 and spreading  
of H3K27me3
We noted a strong similarity between the phenotype of H3K27M 
cells in which PRC2 is recruited but exhibits diminished activity 
and that of PRC2 mutants that are deficient in allosteric activation 
(25). Thus, we next tested whether H3K27M may preferentially im-
pair allosteric activation of PRC2. To accomplish this, we incubated 
PRC2 with increasing amounts of the allosterically activating 
H3K27me3 peptide in the presence of SAM and nucleosomes com-
prising either H3K27M or control H3K27A (HA-tagged H2A; 
Fig 5A). PRC2 activity was subsequently assessed by adding WT 
nucleosomes (distinguished by a C-terminal FLAG-tagged H3; 
Fig. 5A). Strikingly, while there was little difference in the absence 
of H3K27me3 peptide, PRC2 was refractory to stimulation by 
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H3K27me3 in the presence of H3K27M nucleosomes (Fig. 5B). 
Furthermore, the presence of H3K27me3 selectively increased the 
binding affinity of PRC2 toward H3K27M-containing chromatin 
(Fig. 5C). Combined, these results indicate that the allosterically 
activated form of PRC2 (25, 27) binds stronger to H3K27M and that 
PRC2 catalysis is more sensitive to H3K27M.
To examine whether a similar defect in catalysis exists in H3K27M- 
bearing glioma, we used an internal spike-in normalized ChIP-seq 
protocol and directly compared H3K27me3 deposition in two inde-
pendent H3K27M DIPG and H3K27WT glioma cell lines (selected 
on the basis of being pediatric World Health Organization grade 
IV, matched culture conditions, and IDH1 WT). The H3K27me3 
peaks in the H3K27M cells appeared sharper and larger in magnitude 
than those observed in WT cells (Fig. 5D, left). Genome-wide anal-
ysis confirmed these observations, and more importantly, revealed 
that the “remaining” H3K27me3 peaks in H3K27M glioma were 
not subject to spreading into large repressive H3K27me-containing 
domains as observed in WT cells, a process likely dependent on 
PRC2-mediated allosteric activation (Fig. 5D, right) (25, 27). Our 
results are consistent with a broader mechanism of K-to-M substitu-
tions, as evidenced in Schizosaccharomyces pombe, wherein H3K9M 
induces a gain in H3K9me3 and its methyltransferase (Clr4) at 
H3K9me3 nucleation sites, while H3K9me3 spreading across 
domains is lost (16). Our results account for the recent descriptions 
of H3K27M isogenic and glioma cells wherein there is a focal gain 
in H3K27me3 at previously established PRC2 target loci that are CpG 
island dense (5, 7, 8, 12). Thus, by impairing allosteric activation 
of PRC2, and hence spreading H3K27me3 (25, 27), H3K27M achieves 
both a global loss of H3K27me3 and a focal accumulation of H3K27me3 
at PRC2 recruitment sites.
Altered histone modification landscape in H3K27M DIPG
Given the widely documented cross-talk among histone modifications, 
we tested whether the presence of H3K27M might affect the global 
histone modification landscape that could further affect PRC2 
activity, resulting in an aberrant epigenetic profile in DIPG. In H3K27M- 
bearing DIPGs, a few histone modifications such as H3K27 acetyla-
tion have already been shown to increase in concert to the decrease 
in H3K27me3 (3, 4, 12, 28). However, a systematic analysis of the 
histone modification profile of DIPGs has so far been hampered, 
perhaps by the scarcity of suitable WT controls, given that most of 
DIPGs carry the H3K27M mutation. Here, we were able to use the 
same quantitative histone modification MS approach as above on a 
panel of human primary H3K27WT glioma cell lines, two different 
H3K27WT DIPGs, and four different H3K27M DIPGs to identify 
global histone modification alterations against a relevant control 
background. Consistent with other studies was a large-scale gain of 
histone acetylation in H3K27M DIPG (fig. S5). However, we ob-
serve that the largest gain of acetylation is on the H4 tail (~20% 
gain). This finding suggests that histone acetylation events beyond 
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the relatively smaller net gain in H3K27 acetylation (~0.3%) reported 
here (fig. S5) and elsewhere (3, 6, 29) might be important drivers of 
the disease.
The most marked result was a significant gain in H3K36me2 
within H3K27M DIPG cells (Fig. 6A). ChIP-seq indicated higher 
levels of H3K36me2 on H3K36me2 target genes in K27M DIPG 
relative to WT (Fig. 6, B and C). In our isogenic H3K27M 293 T-REx 
system, we further observed an invasion of H3K36me2 largely into 
former PRC2 domains that lost H3K27me3 (fig. S6). These alterations 
in the euchromatic H3K36me2 domains and the corresponding 
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heterochromatic H3K27me3 domains are reminiscent of sarcoma 
cells that express H3K36M and exhibit dampened H3K36 methyl-
transferase(s) activity, leading to abnormal deposition of H3K27me3 
(30). Because of the heterogeneity of pediatric glioma culture cell 
lines, we selected a WT (DIPG X) and a K27M (DIPG XIII) cell line to 
compare by RNA sequencing (RNA-seq), as these are better matched 
with respect to both being DIPG, as well as their growth properties 
as nonadherent tumorspheres. As expected, the regions that gain 
H3K36me2 in K27M DIPG also show up-regulation of those genes 
(fig. S7A) and are associated with proneuronal phenotypes, cancer 
pathways, and cell adhesion phenotypes seen in H3K27M DIPG by 
KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway anal-
ysis (fig. S7B). Thus, in each of these cases, the K-to-M mutations 
disrupt heterochromatic and euchromatic domains that have po-
tential to drive aberrant gene expression patterns important for 
proliferation, cancer stem cell properties, and oncogenesis (4–7).
DISCUSSION
A primary challenge in the H3K27M field has been to resolve the 
contradictory observations indicating that PRC2 has a high affinity 
for H3K27M peptides, yet PRC2 and H3K27M are often mutually 
excluded from chromatin in H3K27M DIPG (4, 6, 9, 10). Our studies 
revealed that interaction of H3K27M with PRC2 is a dynamic process 
that cannot be captured by static, steady-state approaches. Namely, 
there is an initial phase after H3K27M is expressed and incorporated 
into chromatin, followed by PRC2 recruitment to H3K27M-containing 
chromatin, presumably due to its higher affinity toward H3K27M 
(Fig. 2C). However, in the next phase, PRC2 is released from 
H3K27M, as they do not colocalize at steady-state conditions in both 
isogenic 293 T-REx systems (e.g., this study, Figs. 2 and 3) and the 
H3K27M DIPG themselves (6). This dynamic model therefore ac-
commodates both the finding of high H3K27M and PRC2 affinity 
in select assays and their failure to be stably colocalized on chromatin 
in cells. In line with the more fluid effect of H3K27M is a recent 
high-resolution imaging study suggesting that, although H3K27M 
does not change the amount of PRC2 bound to chromatin, it can 
increase the time needed for PRC2 to find and select its target 
chromatin loci (31). An implication of these studies is that PRC2 is not 
stable on H3K27M-containing chromatin, an effect with marked 
resemblance to the recently proposed “hit and run” hypothesis of 
PRC2, where core PRC2 devoid of “stabilizing” components such as 
MTF2 and JARID2 is less stable on chromatin (27). These findings 
therefore set the stage for future proteomic studies designed to test 
whether PRC2 might exhibit a decreased association with these sta-
bilizing cofactors, whether the PRC2 core complex is subjected to 
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other more direct effects through its association with H3K27M, and/or 
whether there is a rapid change in the epigenome by the gain of 
H3K36me2 (this study) and H3K27ac (6).
One of the most unexpected findings in our study was a second, 
previously unknown mode of PRC2 inhibition that apparently per-
sists even after its dissociation from H3K27M (Fig. 4). This mode of 
inhibition was more severe as the concentration of SAM increased, 
suggesting that the PRC2 bound and/or released from K27M might 
have a defect in SAM turnover, thereby delaying catalysis (9). The 
other possibility is that H3K27M might inhibit EZH2 automethylation 
(32, 33), eventually influencing the activity of PRC2 on chromatin. Re-
cent studies from our group and others revealed novel automethylation 
sites on EZH2 and highlighted the impact of EZH2 automethylation 
on PRC2 activity (32, 33). It is intriguing to speculate that EZH2 
automethylation could stably change the conformation of the PRC2 
complex, thereby altering its activity on chromatin. Seemingly, in line 
with a lasting effect of H3K27M on PRC2 is a recent study showing 
that, while the levels of PRC2 bound to chromatin do not change, 
the search time of PRC2 for chromatin is increased in cells that ex-
press H3K27M (31). While other variables such as lower H3K27me3 
levels may affect PRC2 search time, it is consistent with our findings 
that there may be a lasting change in PRC2 following its dissociation 
from H3K27M-containing chromatin that affects its later function.
Our mechanistic studies were also able to give insight into the 
paradoxical observation that, despite a widespread loss in H3K27me3, 
there are a smaller number of loci that actually gain H3K27me3 in 
DIPG at steady state (4, 5, 7, 12). We showed that H3K27M has a 
strong inhibitory effect on the allosterically activated form of PRC2 
(Fig. 5), an effect similar to the one previously reported using struc-
tural studies (9). To put our finding in the context of the current 
literature, the initial step of allosteric activation of PRC2 is its binding 
to H3K27me3, the terminal enzymatic product of PRC2, through its 
essential EED subunit. The result is a conformational change in 
EZH2 that stabilizes its catalytic SET domain, leading to a substantial 
enhancement of its HMT activity (9, 34). This positive feedback 
loop facilitates the spreading of H3K27me2-3 from PRC2 recruitment 
sites (27, 35). We postulate that the allosterically activated form of 
PRC2 preferentially binds H3K27M and then becomes less active; 
however, it is still recruited to strong polycomb loci in H3K27M 
cells. This less active version of PRC2 would be much less efficient at 
spreading H3K27me3 (25), leading to a global loss of H3K27me3- 
decorated repressive domains. Yet, the less catalytically active PRC2 
might still accumulate at those polycomb foci, leading to an overall 
gain in the focal concentration of H3K27me3 at steady state. This 
hypothesis is in keeping with the gain of H3K27me3 at select re-
gions, despite the more global loss in PRC2 activity.
In the context of the broader chromatin landscape in H3K27M, we 
showed both large gains in histone acetylation (fig. S5), as previously 
reported (3, 6, 12), and the novel and robust increase in another 
histone modification associated with transcription, H3K36me2 (Fig. 6). 
On the basis of the recent studies suggesting that disrupting the ba-
lance of PRC2 activity and H3K36me levels can drive oncogenesis, 
we speculate that high H3K36me2 levels might represent a core feature 
of H3K27M DIPG (30). Note that, given the heterogeneity present 
within H3K27M DIPG compared to H3WT glioma, more work is 
needed to better understand the precise contributions of H3K36me2 
to transcriptional programs that might drive oncogenesis, specifically 
in H3K27M DIPG. These studies of the downstream effects of 
H3K36me2 will likely be fruitful since readers of this modification, 
as well as the enzymes that place this modification, are potentially 
drugable therapeutic vulnerabilities in DIPG. Targeting oncogenic 
chromatin features, such as residual PRC2 activity as well as the gain 
of histone acetylation marks and their readers, has been shown to 
decrease the hallmarks of DIPG growth and aggression in preclinical 
models (2, 5, 6, 29, 36). Therefore, combining biochemistry with 
mechanistic studies, proteomics, and DIPG disease model systems 
promises not only to shed light on the underlying biology but also 
to reveal novel targets, alone or in combination, for therapeutic in-
tervention in this otherwise intractable disease.
MATERIALS AND METHODS
Cell culture models and tissue preparation
A complete list of cell lines and in vivo H3K27M model systems can 
be found in table S1. Culture methods are briefly described below.
Mouse stem cells and mNEURON differentiation
E14 mESCs were cultured as described previously (17). Differentiation 
to cervical mNEURONs is detailed in (17), but briefly, ESCs were 
plated at low density in the absence of mitogenic factors to form 
embryoid bodies. Two days later, media were supplemented with 
1 M retinoic acid and 0.5 M smoothened agonist. Cells were har-
vested 4 days later, with one media replenishment for 2 days.
Human brain tumor models
Patient-derived glioma cell lines, including DIPG cell lines (see table 
S1 for source), were cultured in tumor stem cell media as described 
(37, 38). Human neural stem cells were derived and cultured as de-
scribed previously (39). New York University (NYU) patient–derived 
tumor cell line generation has been approved by the NYU Institu-
tional Review Board (IRB) (no. S15-01228). Pathological diagnoses 
of primary tumors, from which cell lines were derived, were per-
formed by a board-certified neuropathologist (M.S.), and molecular 
characteristics were established at an NYU Clinical Laboratory 
Improvement Amendment (CLIA)–certified molecular pathology 
laboratory. Furthermore, relevant tumor sample collection and mo-
lecular profiling were approved by the NYU IRB (nos. S12-00865 and 
S14-00948, respectively). All human tumor samples were reviewed, 
and diagnosis was performed by a board-certified neuropathologist 
(M.S.) in a CLIA-certified pathology laboratory.
Generation of isogenic cell lines
mESC model
The H3K27M mutation was introduced into the H3F3A locus 
through CRISPR-Cas9 engineering as described in (17). Briefly, guide 
RNA (gRNA) directed at H3F3A were designed using the tool (http://
crispr.mit.edu/design) and cloned into the SpCas9-2A-GFP vector 
(plasmid no. 48138, Addgene). mESCs were cotransfected with the 
Cas9, gRNA, and donor DNA template to promote homology- 
directed repair, resulting in an M substitution at K27 of H3F3A (i.e., 
AAG to ATG). Cells containing the Cas9 vector were selected by 
green fluorescent protein (GFP) and fluorescence-activated cell 
sorting (FACS), and single cells were plated at low density. Individual 
colonies were picked 5 to 7 days later. Individual clones bearing the 
mutation were harvested and genotyped using Sanger sequencing. 
Colonies positive for the H3F3A K27M substitution were passaged 
at least five times to confirm purity of the population.
293 T-REx model
Cells were cultured using standard media (Dulbecco’s modified Eagle’s 
medium + fetal bovine serum + metabolic support). Stable cell lines 
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in which the expression of the integrated transgene, either H3.3K27WT or 
H3.3K27M, under the control of doxycycline were generated by 
transfecting pINTO-NFH vector (40). Stable cell lines were selected 
using zeocin-selectable (200 g/ml) and blasticidin-selectable 
(10 g/ml) markers encoded in the pINTO-NFH vector. Stable in-
tegration was subsequently confirmed by Sanger sequencing. To 
induce expression of the H3.3K27WT or H3.3K27M transgenes, 
doxycycline (1 g/ml) was added at the appropriate time point be-
fore harvesting.
A derivative of 293 T-REx suitable for PRC2 purification was 
generated as follows. A 6×His-tagged EZH2 complementary DNA 
(cDNA) and FLAG-tagged EED cDNA were subcloned into the 
pLVX-EF1-IRES-mCherry lentiviral vector (Clontech). Cells stably 
expressing both 6×His-tagged EZH2 and FLAG-tagged EED cDNAs 
were generated by lentiviral transduction. For the production of 
viral particles, lentiviral vectors were cotransfected with pcREV, 
BH10, and pVSV-G into 293 T-REx cells. The virus-containing 
medium was collected 48 hours after transfection. The viruses car-
rying 6×His-tagged EZH2 or FLAG-tagged EED were mixed in a 
1:1 ratio before infection of 293 T-REx cells. Polybrene was added 
to the viral medium at a concentration of 8 g/ml. Infected cells were 
selected using mCherry expression by FACS.
Purification of recombinant proteins
To purify the human PRC2 core complex, FLAG-tagged EED, 
6×His-tagged EZH2, SUZ12, and RBAP48 were cloned into the 
baculovirus expression vector pFASTBac1 (Invitrogen). Re-
combinant PRC2 was produced in SF9 cells grown in SF-900 III 
SFM (Invitrogen). After 60 hours of infection, SF9 cells were resus-
pended in BC150 [25 mM Hepes-NaOH (pH 7.8), 1 mM EDTA, 
150 mM NaCl, 10% glycerol, and 1 mM dithiothreitol (DTT)] with 
0.1% NP40 and protease inhibitors [1 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 mM benzamidine, pepstatin A (1 g/ml), 
leupeptin (1 g/ml), and aprotinin (1 g/ml)]. Cells were lysed by 
sonication (Sonic Dismembrator model 100, Fisher Scientific), and 
PRC2 complexes were purified through Ni-NTA agarose beads 
(Qiagen), FLAG-M2 agarose beads (Sigma-Aldrich), and Q Sepharose 
beads (GE Healthcare).
Purification of PRC2 from 293 T-REx
After expressing H3.3K27M or H3.3K27WT using doxycycline 
(1 g/ml) for 72 hours, cells grown in plates (40 cm by 15 cm) were 
harvested for each condition. Nuclei were purified using a standard 
hypotonic lysis approach, and nuclear extract was prepared using 
BC400 buffer [20 mM tris (pH 7.9), 400 mM KCl, 0.2 mM EDTA, 
0.5 mM DTT, 20% glycerol, 0.05% NP-40, 1 mM PMSF, 1 mM 
benzamidine, pepstatin A (1 g/ml), leupeptin (1 g/ml), and aprotinin 
(1 g/ml)]. The first purification step used Ni-NTA agarose beads 
to purify EZH2 that had a 6×His tag, followed by Q Sepharose. The 
eluate was then further purified using FLAG-M2 agarose beads 
to isolate the complex containing FLAG-tagged EED, followed by 
another Q Sepharose. PRC2 was eluted in BC500 [20 mM Hepes-
NaOH (pH 7.8), 500 mM NaCl, 0.02% NP-40, 10% glycerol, 1 mM 
PMSF, and 1 mM benzamidine]. Components of purified PRC2 
were visualized by silver staining after SDS–polyacrylamide gel 
electrophoresis (PAGE), and its activity was gauged in HMT assays. 
PRC2 was also purified from 293 cells containing FLAG-tagged 
EED, but not 6×His-tagged EZH2, using FLAG-M2 agarose and Q 
Sepharose.
Nucleosome reconstitution
Purification of recombinant histones, refolding recombinant octamers, 
and reconstitution of nucleosomes were generated as described pre-
viously (25).
HMT assay
Standard HMT assays were performed as described (25), unless 
otherwise stated in the figure legends. Briefly, the reaction was per-
formed in a total volume of 15 l of HMT buffer [50 mM tris-HCl 
(pH 8.5), 5 mM MgCl2, and 4 mM DTT] with the indicated amounts 
of recombinant human PRC2 complex (EZH2, EED, SUZ12, and 
RBAP48), 500 nM of 3H-labeled SAM (PerkinElmer). Specific con-
ditions related to the main figures are presented below with the sup-
plementary figures’ detailed information provided.
All reaction mixtures were incubated for 60 min at 30°C and 
stopped by the addition of 4-l SDS buffer [0.2 M tris-HCl (pH 6.8), 
20% glycerol, 10% SDS, 10 mM -mercaptoethanol, and 0.05% bro-
mophenol blue]. After HMT reactions, samples were incubated for 
5 min at 95°C and resolved on SDS-PAGE gels. The gels were then 
subjected to Coomassie blue staining for protein visualization or wet 
transfer of proteins to 0.45-m polyvinylidene difluoride (PVDF) 
membranes (Millipore). The radioactive signals were detected by 
exposure on autoradiography films (Denville Scientific).
PRC2 quantitation by MS
Cell lysate preparation
Cells were harvested by counting each cell line in quadruplicate and 
were resuspended in a known volume of lysis buffer [8 M urea, 1% 
CHAPS, and 20 mM Hepes (pH 8.0)]. The suspension was pulsed 
six times with a sonic dismembrator on ice and was rotated end 
over end for 1 hour at 4°C. DNA was pelleted, and cell lysate was 
prepared for MS analysis.
Cell lysates were prepared using the filter-aided sample prepara-
tion (FASP) method. Briefly, 50 to 200 g of protein per sample, at 
a concentration of 1 to 10 g/l, was reduced with DTT (final con-
centration of 3 mM) at 57°C for 1 hour and loaded onto a MicroCon 
30-kDa centrifugal filter unit pre-equilibrated with 200 l of FASP 
buffer A [8 M urea and 0.1 M tris-HCl (pH 7.8)] (Millipore). Fol-
lowing three washes with FASP buffer A, lysates were alkylated on a 
filter with 50 mM iodoacetamide for 45 min in the dark. Filter- 
bound lysates were then washed three times each with FASP buffer 
A and FASP buffer B [100 mM ammonium bicarbonate (pH 7.8)] 
and were digested overnight at room temperature with trypsin 
(Promega) at a 1:100 ratio of enzyme to protein. Peptides were 
eluted twice with 0.5 M NaCl. Tryptic peptides were desalted 
using an UltraMicro Spin Column, C18, (Harvard Apparatus), 
and the desalted peptide mixture was concentrated in a SpeedVac 
concentrator.
Targeted MS assay development
Peptides used in this assay were selected on the basis of a series of 
experiments. First, we compiled data from the Global Proteome 
Machine Database (GPMDB) for each of the three proteins (41). 
GPMDB is a repository of the results of MS-based proteomics ex-
periments. The data collected included the peptides and the charge 
states identified, their uniqueness to the protein, and the number of 
times that each was identified. The most often identified unique 
peptides and charge states of EED, EZH2, and SUZ12 were com-
pared to the results of the recombinant analysis to generate a list of 
approximately five candidate peptides per protein.
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Next, an equal molar trypsin-digested mixture of the three 
recombinant mouse PRC2 proteins (EED, EZH2, and SUZ12) was 
analyzed on a Q Exactive mass spectrometer (Thermo Fisher Scientific) 
using a data-dependent method. A list of identified proteotypic 
peptides was compiled. This list of peptides was used to generate a 
target list in the Skyline Software, which was used to build the tar-
geted MS2 method. An aliquot of an mESC lysate was analyzed 
using this method. Raw files were uploaded to the Skyline Software. 
Candidate peptides were evaluated on the basis of the chromato-
graphic peak shape, ionization efficiency, coverage of fragmentation, 
level of interference from other peptides within the isolation window, 
and the presence of product ions that differentiate the endogenous 
and heavy-labeled peptide. Two to three of the strongest candidate 
peptides were custom synthesized (New England Peptide) with an 
isotopically heavy C-terminal residue.
Targeted MS analysis
The peptides were spiked into an aliquot of the cell lysate at a level 
ranging from 100 amol to 5 fmol. The peptide mixture was loaded 
onto an Acclaim PepMap trap column in line with an EASY-Spray 
PepMap C18 analytical high-performance liquid chromatography 
(HPLC) column (inner diameter, 50 cm by 75 m) with a 2-m bead 
size using the auto sampler of an EASY-nLC 1000 HPLC (Thermo 
Fisher Scientific). The peptides were gradient eluted into a Q Exactive 
mass spectrometer (Thermo Fisher Scientific) using a 60-min gra-
dient from 5 to 23% of solvent B (solvent A, 2% acetonitrile and 
0.5% acetic acid; solvent B, 90% acetonitrile and 0.5% acetic acid), 
followed by 20 min from 23 to 45% of solvent B. Solvent B was taken 
to 100% in 10 min and held at 100% for 20 min. High-resolution full 
MS spectra were acquired with a resolution of 70,000, an automatic 
gain control (AGC) target of 1 × 106, a maximum ion time of 120 ms, 
and a scan range of 300 to 1500 mass/charge ratio (m/z). Following 
each full MS scan, targeted high-resolution high-energy collisional 
dissociation tandem MS (MS/MS) spectra were acquired on the basis 
of the inclusion list containing the m/z values of the unlabeled en-
dogenous and stable isotope–labeled standard PRC2 peptides. All 
MS/MS spectra were collected using the following instrument pa-
rameters: resolution of 17,500, AGC target of 2 × 105, maximum ion 
time of 120 ms, one microscan, isolation window of 2.0 m/z, fixed 
first mass of 150 m/z, and normalized collision energy of 27. Peptides 
not behaving linearly in lysate were excluded from future quantitation.
Quantitative experiments were conducted in two ways: (i) five-
point calibration curve (500 amol to 5 fmol) of standard peptides 
spiked into a constant amount of lysate or (ii) a single-point calibra-
tion of standard peptides spiked into a constant amount of lysate in 
triplicate in a concentration close or equal to the endogenous level.
Data analysis and validation
Raw files were uploaded to Skyline Software (64 bit) version 3.6.0.10162 
for analysis. The top three or four product ions were used to quan-
tify the light (endogenous) and stable isotope–labeled standard 
peptides (see data file S1). Total product ion area values were calcu-
lated for the light and heavy peptides.
When a calibration curve was generated, the total product ion 
area values for each of the stable isotope–labeled standard peptides 
were plotted, a linear trendline was fit to the data, and the line equa-
tion was used to calculate the femtomoles of endogenous peptide in 
the lysate. The average, SD, and the coefficient of variance across 
the triplicates are reported for all lysates.
To calculate the number of each PRC2 subunit (EZH2, EED and 
SUZ12) per cell, the average femtomoles is for each peptide quantified 
of that subunit were computed and converted to number of molecules 
using Avogadro’s number and was divided by the number of cells 
analyzed to obtain molecules per cell. Total PRC2 per cell was cal-
culated by taking the average of all subunits.
A few attempts have been made to infer the number of PRC2 
molecules per nucleus using a variety of imaging and enzyme kinetic 
techniques. Reports vary from numbers as low as 6000 [acute lym-
phoblastic leukemia/myeloma; (42)] to ~40,000 [Drosophila neuro-
blast; (43)] and as high as 20,006,965 in a Drosophila salivary gland 
(44). While our methods provided slight variations on these num-
bers, they are well within the range and ordinal differences reported, 
adding validity to these various methods of PRC2 quantitation.
Histone extraction, MS, and analysis of histone 
modifications
Histone extraction, MS, and analysis of histone modifications were 
based on previously published methods (45,  46). Quantifications 
for the histone modifications are presented in data file S2. All cell 
lines used for the analysis are noted in table S1.
ChIP-seq experiments
ChIP was performed as described previously (40). Briefly, H3.3K27M 
was induced by doxycycline (1 g/ml) for 72 hours, cross-linked 
with 1% formaldehyde, and harvested following glycine treatment 
to quench the formaldehyde. Nuclei were extracted, sonicated using 
the Diagenode Bioruptor to produce chromatin fragments at an 
average size of 300 to 500 bp. Chromatin was then precleared with 
bovine serum albumin (BSA)–blocked magnetic Dynabeads. Each 
ChIP was performed with an internal spike-in standard correspond-
ing to 1:200 of cross-linked, sonicated, and precleared Drosophila 
chromatin. The Drosophila-specific H2A.V antibody was also added 
at ~1:20 of the primary ChIP antibody. The immunoprecipitation 
was performed using antibodies to the appropriate protein (table S2) 
and 30 l of BSA-blocked Dynabeads. Immunoprecipitated chro-
matin bound to the beads was then washed in radioimmunoprecip-
itation assay buffer. Chromatin was de–cross-linked, and proteins 
were removed by proteinase K. DNA libraries were constructed, 
barcoded as in (17), and subjected to SR50 sequencing on an Illumina 
HiSeq 2500 or Illumina NextSeq 500.
ChIP-seq data processing
Quality of sequencing was assessed with FastQC v0.11.4 (www.
bioinformatics.babraham.ac.uk/projects/fastqc/). Reads having less 
than 80% of quality scores above 25 were removed with NGSQC-
Toolkit v2.3.3 (47) using the command IlluQC.pl -se $file_path N A -l 
$percent -s $threshold -p $nb_cpu -o $out_path. Reads were aligned 
to the human hg19 reference genome from Illumina iGenomes 
University of California, Santa Cruz (UCSC) collection using bowtie 
v1.0.0 (48), allowing three mismatches and keeping uniquely aligned 
reads (bowtie -q -v 3 -p $nb_cpu -m 1 -k 1 --best --sam --seed 1 
$bowtie_index_path "$file_path"). Sam (sequence alignment/map) 
outputs were converted to Bam (binary alignment/map) with SAM-
tools v1.0.6 (49) (samtools view -S -b $file_path -o $out_path/$file_
name.bam) and were sorted with Picard tools v1.88 (http://broadinstitute.
github.io/picard; java -jar SortSam.jar SO=coordinate I=$input_
bam O=$output_bam). Data were further processed with Pasha 
v0.99.21 (50) with the following parameters: WIGvs = TRUE, 
incrArtefactThrEvery = 7,000,000, elongationSize = NA (not avail-
able). Fixed steps wiggle files were converted to bigwigs, with the 
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script wigToBigWig available on the UCSC Genome Browser website 
(http://hgdownload.soe.ucsc.edu/admin/exe/).
Spike-in normalization was achieved using Drosophila melanogaster 
DNA aligned to Illumina iGenomes dm3, as mentioned above (51). 
Endogenous and exogenous scaling factors were computed from 
the bam files [1/(number_mapped_reads/1,000,000)]. Endogenous 
scaling factors were applied to the data before input subtraction 
(without scaling). The reads per million reads normalization was 
then reversed before scaling with exogenous factors. The scripts 
used to perform spike-in scaling was integrated in the Bioconductor 
package ChIPSeqSpike (https://bioconductor.org/packages/3.7/bioc/
html/ChIPSeqSpike.html).
Domain selection and peak calling
The different domains were identified in 293 T-REx cells at all 
time points with hiddenDomains v3.0 (52), with the command 
“hiddenDomains -g $chromInfo_file -b $bin_size -t $expBam -c 
$inputbam -o $outputFilePrefix.” A window size of 50 or 100 kb 
was used (Figs. 2 and 3 and fig. S3 for example). To more precisely 
identify overlap between ChIPs within these domains, peaks were 
detected within the domain as noted in the main text and figure 
legends. Briefly, peaks were detected using SeqMonk v1.41 (www.
bioinformatics.babraham.ac.uk/projects/seqmonk/), merging bio-
logical replicates using a 1 × 10−5 cutoff, filtered to identify only 
peaks contained within the domains, and transformed to the heat-
map representation noted below (Figs. 2 and 3).
To retrieve the common K27me3 peaks by overlap in DIPG cells 
(Fig. 5), MACS2 v2.1.0 was used (macs2 callpeak -t $bam_file_vector -c 
$input_file_vector -n $experiment_name --outdir $output_folder_
nomodel_broad -f $format -g $genome_size -s $tag_size --nomodel -- 
extsize $elongation_size --keep-dup $artefact_threshold --broad -- 
broad-cutoff 1 × 10−5).
Metagene profiles and heatmaps
Metagene profiles and heatmap were largely generated with the 
Bioconductor package SeqPlots v1.8.1 (53) in command line. Mean, 
95% confidence intervals, and SE are indicated on the profiles in the 
figures. Heatmaps for Figs. 2 and 3 and quantitative trend plots for 
Fig. 5 [1727 or all RefSeq (Reference Sequence) genes] were gener-
ated with deepTools v2.3.3 (54).
Western blot
Western blots were performed largely as in (25, 27) with bis-tris– 
resolving gels and were transferred to 0.45-m PVDF membranes. 
The antibodies used are indicated in the main text and table S2.
General quantitation and data analysis
Band intensity for Western blots and autoradiography experiments 
were quantitated after normalization using ImageJ. Where appro-
priate, simple a priori hypotheses were tested by analysis of variance 
(ANOVA), followed by Fisher’s least significant difference. Experi-
mental  was set to 0.05 for all experiments.
SUPPLEMENTARY MATERIALS
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Fig. S1. PRC2 quantitation across cell types.
Fig. S2. H3K36me2 is the predominant modification adjacent to K27M, and K27M is deposited 
primarily into active regions.
Fig. S3. The level of H3K27me3 at PRC2 common targeting domain is reduced in H3K27M cells.
Fig. S4. Cell line generation and characterization of PRC2 purified from H3.3K27M or 
H3.3K27WT cells.
Fig. S5. Alterations in histone modifications in H3K27M DIPG.
Fig. S6. Spreading of K36me2 in the K27M 293 T-REx cells.
Fig. S7. Select transcriptional changes associated with K36me2 in comparable K27M DIPG cell 
lines.
Table S1. Cell lines and tumor samples used in this study.
Table S2. Antibodies and relevant ChIP conditions used in this study.
Data file S1. Related to PRC2 quantitation.
Data file S2. Histone modification quantitation.
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